Hologic, Inc. (NASDAQ:HOLX – Get Free Report) insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Hologic Stock Performance
HOLX opened at $83.64 on Friday. The stock has a market cap of $19.52 billion, a PE ratio of 42.67, a P/E/G ratio of 2.64 and a beta of 0.99. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $84.67. The stock’s 50 day simple moving average is $76.29 and its 200-day simple moving average is $75.65. The company has a current ratio of 3.99, a quick ratio of 3.29 and a debt-to-equity ratio of 0.51.
Hologic (NASDAQ:HOLX – Get Free Report) last announced its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the firm earned $0.93 EPS. Hologic’s quarterly revenue was up 2.7% on a year-over-year basis. Sell-side analysts forecast that Hologic, Inc. will post 4.08 EPS for the current year.
Hedge Funds Weigh In On Hologic
Analyst Ratings Changes
A number of research firms have recently issued reports on HOLX. StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Stephens reiterated an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research report on Tuesday, July 30th. Evercore ISI upped their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 30th. JPMorgan Chase & Co. upped their target price on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Hologic in a report on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $87.60.
Read Our Latest Report on HOLX
About Hologic
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Read More
- Five stocks we like better than Hologic
- Consumer Discretionary Stocks Explained
- MarketBeat Week in Review – 8/5 – 8/9
- What is Put Option Volume?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.